Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 7/20 | 0.78 |
| ▸ | MEN1 | O00255 | 6/20 | 0.78 |
| ▸ | RECQL | P46063 | 1/20 | 0.78 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.45 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.45 |
| ▸ | FEN1 | P39748 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 2/20 | 0.44 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5722072 | 0.96 | KMT2A (0.71) | KMT2AMEN1RECQLMAPTPABPC1 | |
| SCHEMBL6400580 | 0.89 | MEN1 (0.62) | KMT2AMEN1RECQLMAPTPABPC1 | |
| SCHEMBL6404282 | 0.89 | MEN1 (0.62) | KMT2AMEN1RECQLMAPTPABPC1 | |
| SCHEMBL6398727 | 0.89 | MEN1 (0.62) | KMT2AMEN1RECQLMAPTERCC5 | |
| SCHEMBL6399978 | 0.89 | MEN1 (0.62) | KMT2AMEN1RECQLMAPTERCC5 | |
| SCHEMBL5721911 | 0.88 | KMT2A (0.60) | KMT2AMEN1RECQLMAPTPABPC1 | |
| SCHEMBL6404895 | 0.88 | KMT2A (0.60) | KMT2AMEN1RECQLMAPTPABPC1 | |
| Bromide SCHEMBL6074358 | 0.88 | KMT2A (1.00) | KMT2AMEN1RECQLMAPTPABPC1 | |
| SCHEMBL6399605 | 0.88 | MEN1 (0.74) | KMT2AMEN1RECQLMAPTPABPC1 | |
| SCHEMBL6401164 | 0.86 | KMT2A (0.76) | KMT2AMEN1RECQLMAPTPABPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050272936-A1 | Imidazolium cxcr3 inhibitors | SMITHKLINE BEECHAM CORPORATION | 2005-12-08 | — | — | US | disclosed |
| US-20050215787-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF PURINES | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2005-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215787-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF PURINES | PNP, HPRT1, NUDT1 | KMT2A 2307/4885MEN1 2675/4885RECQL 135/4885 |
| US-20050272936-A1 | Imidazolium cxcr3 inhibitors | CXCR3, CXCR1, CCR7 | KMT2A 4040/4885MEN1 3721/4885RECQL 1290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.